Potential treatment of Parkinson’s disease with omega-3 polyunsaturated fatty acids
The DOI matches its Crossref record, with a small difference in title or year; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is characterized by dysfunction of the nigrostriatal system, loss of dopamine neurons and intracellular aggregation of α-synuclein. Recently, both clinical and experimental studies have reported that neuroinflammation and oxidative stress markedly contribute to the etiology of PD. Current clinical pharmacotherapies only temporarily relieve the symptoms of PD, accompanied by many side effects. Hence, searching for natural anti-inflammatory, anti-oxidative and neuroprotective agents has received great attention. Polyunsaturated fatty acids (PUFAs), especially omega (n)-3, are essential lipid nutrients in the human diet and important components of cell membranes. Together by competing with the production of n-6 PUFAs, the precursors of inflammatory mediators, n-3 PUFAs can inhibit microglial activity and neuroinflammation, protect astrocyte function to produce neurotrophins, thereby normalizing neurotransmission and improving neurodegeneration. Thus, with regard to the hypotheses of PD, our and other's recent studies have demonstrated that n-3 PUFAs may improve PD by inhibiting proinflammatory cytokine release, promoting neurotrophic factor expression, recovering mitochondrial function and membrane fluidity, decreasing the levels of oxidant production, maintaining α-synuclein proteostasis, calcium homeostasis, axonal transport, and reducing endoplasmic reticulum stress. This review mainly introduces and analyzes the effect of n-3 PUFA treatments on PD-related behavioral and neuropathological abnormalities in clinical patients and different cellular and animal models of PD. Finally, the limitations and future work in n-3 PUFAs anti-PD area are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Besides having a crucial role in membrane fluidity and a broad spectrum of activities, ω3 may be also beneficial at several levels of the neuronal degenerative process observed in PD [451].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [451]
Citations
Cites
Free radicals and antioxidants in normal physiological functions and human disease
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.07.001 · Cited by 14,269 · cited 1×
“Eventually, catalase converts H2O2 to molecular oxygen and water [40,41].”
BackgroundNeurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 1×
“Phosphatase and Tensin Homolog (PTEN)-induced putative kinase 1 (PINK1) and Leucine-Rich Repeat Kinase 2 (LRRK2) are considered as risk factors of PD [36].”
BackgroundMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · cited 1×
“SNpc of PD patient’s brain from postmortem examinations [13], a growing number of animal and cell experiments have shown that neuroinflammation isinvolved in the pathogenesis of PD [14,15].”
BackgroundDifferential Roles of M1 and M2 Microglia in Neurodegenerative Diseases
Tang, Y., & Le, W. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9070-5 · Cited by 2,190
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Neuroinflammation and M2 Microglia: The Good, the Bad, and the Inflamed
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-98 · Cited by 1,748
Sofi, F., Abbate, R., Gensini, G. F., & Casini, A. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29673 · Cited by 1,605 · cited 1×
“neurodegenerative diseases such as AD and PD [97].”
BackgroundPharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons
Kim, J., Inoue, K., Ishii, J., Vanti, W. B., Voronov, S. V., Murchison, E., Hannon, G., & Abeliovich, A. (2007) · Science · doi:10.1126/science.1140481 · Cited by 1,187 · cited 1×
“be evaluated in the future [99,100]; (5) the modulation of n-3 PUFAs on microglial M1 and M2, as well as astrocyte A1 and A2 phenotypes and consequence to the neu-”
Background
Research works printed but not linked: 8
- Poewe W, 2017, Nat Rev Dis Primers, 317013
- Xia L, 2017, Exp Ther Med, 14, 5569
- 10.1186/s40035-015-0042-0 · DOI · Paper page
- Watanabe Y, 2005, Med Sci Monit, 11, Ra17
- Yang N, 2019, Neurobiol Aging, 76215, e211
- Orr SK, 2008, Curr Opin Investig Drugs, 9, 735
- Mounsey RB, 2010, Parkinsons Dis, 2011, 1
- Wu Y, 2007, Acta Med Okayama, 61, 147
Cited by
Patel, A., Karageorgou, D., Katapodis, P., Sharma, A. K., Rova, U., Christakopoulos, P., & Μάτσακας, Λ. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2021.06.044 · Cited by 102
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Khalid, W., Gill, P., Arshad, M. S., Ali, A., Ranjha, M. M. A. N., Mukhtar, S., Afzal, F., & Maqbool, Z. (2022) · International Journal of Food Properties · doi:10.1080/10942912.2022.2070642 · Cited by 73
RetractedUnveiling Nature's potential: Promising natural compounds in Parkinson's disease management
Bhusal, C. K., Uti, D. E., Mukherjee, D., Alqahtani, T., Alqahtani, S., Bhattacharya, A., & Akash, S. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105799 · Cited by 77
Davinelli, S., Medoro, A., Intrieri, M., Saso, L., Scapagnini, G., & Kang, J. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.11.017 · Cited by 73
Metadata
- Authors
- Li, P., & Song, C.
- Affiliations
- Guangdong Medical College (CN)
- Guangdong Ocean University (CN)
- Corresponding author
- Song, Cai
- Venue
- Nutritional Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2020-03-03
- Volume
- 25
- Issue
- 1
- Pages
- 180-191
- ISSN
- 1028-415X (ISSN-L)
- 1476-8305
- OpenAlex
- W3010199314
- Cited by
- 74
- References
- 95
- Citations by year
- 2026: 11 · 2025: 11 · 2024: 22 · 2023: 13 · 2022: 11 · 2021: 6
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nutritional Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Parkinson's disease, omega-3 polyunsaturated fatty acids, neuroinflammation, oxidative stress, neuroprotection, alpha-synuclein, microglial activation, inflammatory cytokines, neurotrophic factors, mitochondrial function, membrane fluidity, endoplasmic reticulum stress, calcium homeostasis, axonal transport, nigrostriatal pathway, dopaminergic neurons
- MeSH terms
- Neuroinflammatory Diseases, Animals, Anti-Inflammatory Agents, Antioxidants, Astrocytes, Humans, Nerve Growth Factors, Parkinson Disease, Fatty Acids, Omega-3, Microglia, Oxidative Stress, Neuroprotective Agents, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential treatment of Parkinson’s disease with omega-3 polyunsaturated fatty acids. https://app.cochat.ai/papers/10.1080/1028415x.2020.1735143
- The paper
- Li, P., & Song, C. (2022). Potential treatment of Parkinson’s disease with omega-3 polyunsaturated fatty acids. Nutritional Neuroscience. https://doi.org/10.1080/1028415x.2020.1735143
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.